Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
National Institute of Allergy and Infectious Diseases (NIAID)
With
Upjohn
HIV-infected children are randomized to receive adjunctive therapy with intravenous methylprednisolone or placebo. Treatment is administered for 10 days. Primary antipneumocystis therapy with TMP/SMX or systemic pentamidine is selected by the individual investigator and given for 21 days. Patients are stratified at the time of randomization by the presence or absence of respiratory failure.
Age
0–2
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Concurrent Medication:
Allowed:
Recombinant erythropoietin and any FDA-approved cytokine for management of anemia.
Antiretroviral agents.
Patients must have:
Documented HIV infection.
PCP.
No more than 36 hours of prior primary therapy for confirmed or presumed PCP.
Prior Medication:
Allowed:
Up to 35 hours of primary therapy for confirmed or presumed PCP.
You may not be if
Co-existing Condition:
Patients with the following symptoms and conditions are excluded:
Demonstrated intolerance to steroids.
Requirement for steroids at greater than physiological doses for other medical conditions.
Clareo Health | The Safety and Effectiveness of Methylprednisolone in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Children With AIDS
